Elios Vision completes enrollment for pivotal US clinical trial


The company seeks to replicate European success of the ELIOS procedure in the US market.

A woman with graphics over her eye simulating laser eye surgery. (Image Credit: AdobeStock/blackday)

(Image Credit: AdobeStock/blackday)

Ophthalmic device company Elios Vision, which specializes in micro-invasive glaucoma surgery (MIGS) adoption, announced a “pipeline milestone” ahead of a pivotal trial in the United States. According to a press release, the company has completed enrollment for a trial of more than 300 patients with mild to moderate glaucoma. These patients will be treated with the implant-free ELIOS procedure, in combination with cataract surgery.1

The enrollment milestone reflects Elios Vision’s focus on bringing the ELIOS excimer laser technology to the US market.1 Currently, Elios Vision is seeking FDA approval and adding team members ahead of US commercialization. Earlier this year, Elios Vision announced it had registered the ELIOS technology in the United Kingdom; last December, the company registered its technology in France.

The company acknowledged its success throughout Europe in the press release, with commentary from Keith Barton, MD, FRCP, FRCS, FRCOphth, University College London and Moorfields Eye Hospital, London. “There is clear momentum for the ELIOS procedure across European markets,” Dr Barton said.1 “The ELIOS excimer laser technology is an attractive and widely adoptable option at the time of cataract surgery for glaucoma and cataract surgeons."

At the World Glaucoma Congress in Rome this week, the Elios Vision Europe team will present clinical data and showcase the signature ELIOS procedure during dry lab sessions, the company announced.1

Alongside the trial enrollment news, Elios Vision recognized additions to the US executive team. Frank Shields, previously at Bausch & Lomb, J&J and Ivantis, will lead US sales as President of the Americas. Cari Stone will serve as Senior Vice President of Marketing, bringing 20 years experience in medical devices, biotech and pharmaceuticals. Finally, John Liu was named Senior Vice President of Reimbursement and Market Access. With previous roles at Alcon, Sight Sciences and Allergan, Liu brings 25 years experience to the executive team.

“Completing enrollment of our US clinical trial marks a significant milestone on our journey to advancing the global standard of care in glaucoma,” said Elliot Friedman, Elios Vision Chairman and CEO.1 “Our world class team and KOL’s in Europe and the US allow Elios Vision to establish a significant next-generation MIGS treatment that is implant-free, preserves tissue and has many independent clinical studies demonstrating the powerful efficacy and safety that you would expect from an excimer laser treatment.”

  1. Elios Vision Achieves Pipeline Milestone with Enrollment Completion in U.S. Pivotal Trial, Expands U.S. Pre-launch Team, and Continues to Generate Commercial Uptake in Europe. News release. Elios Vision, Inc., June 28, 2023. https://www.biospace.com/article/releases/elios-vision-achieves-pipeline-milestone-with-enrollment-completion-in-u-s-pivotal-trial-expands-u-s-pre-launch-team-and-continues-to-generate-commercial-uptake-in-europe/
Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.